Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTT | P42858 | 2/20 | 0.59 |
| ▸ | HPGD | P15428 | 7/20 | 0.46 |
| ▸ | MEN1 | O00255 | 3/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.45 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.44 |
| ▸ | BRD4 | O60885 | 1/20 | 0.44 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.41 |
| ▸ | NLRP3 | Q96P20 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29955257 | 1.00 | HTT (0.59) | HTTHPGDMEN1KMT2AALDH1A1 | |
| SCHEMBL23191109 | 0.81 | ENPP2 (0.42) | HTTALDH1A1TRPV1NLRP3 | |
| SCHEMBL173028 | 0.81 | ALDH1A1 (0.56) | HTTHPGDALDH1A1SMN1; SMN2BRD4 | |
| SCHEMBL519364 | 0.79 | NLRP3 (0.45) | HTTHPGDMAPTSMN1; SMN2BRD4 | |
| SCHEMBL1111199 | 0.78 | HTT (0.64) | HTTHPGDMEN1KMT2AALDH1A1 | |
| SCHEMBL15330286 | 0.77 | KDM1A (0.45) | ALDH1A1SMN1; SMN2BRD4TRPV1NLRP3 | |
| SCHEMBL23226566 | 0.76 | HTT (0.61) | HTTHPGDMEN1KMT2AALDH1A1 | |
| SCHEMBL14433200 | 0.76 | HPGD (0.61) | HTTHPGDMEN1KMT2AALDH1A1 | |
| SCHEMBL519912 | 0.75 | AURKA (0.48) | MEN1KMT2ASMN1; SMN2BRD4NLRP3 | |
| SCHEMBL11023258 | 0.75 | HTT (0.59) | HTTHPGDMEN1KMT2AALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 63 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180243298-A1 | TRPV3 MODULATORS | ABBVIE INC. | 2018-08-30 | — | — | US | disclosed |
| US-20170137407-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | INFINITY PHARMACEUTICALS, INC. | 2017-05-18 | — | — | US | disclosed |
| US-20170137407-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | INFINITY PHARMACEUTICALS, INC. | 2017-05-18 | — | — | US | disclosed |
| US-20170137407-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | INFINITY PHARMACEUTICALS, INC. | 2017-05-18 | — | — | US | disclosed |
| EP-2822931-B1 | TRIAZOLONE COMPOUNDS AND USES THEREOF | INCEPTION 2 INC (US) | 2017-05-03 | — | — | EP | disclosed |
| US-9546180-B2 | Heterocyclic compounds and uses thereof | INFINITY PHARMACEUTICALS, INC. (US) | 2017-01-17 | — | — | US | disclosed |
| US-9546180-B2 | Heterocyclic compounds and uses thereof | INFINITY PHARMACEUTICALS, INC. (US) | 2017-01-17 | — | — | US | disclosed |
| US-9546180-B2 | Heterocyclic compounds and uses thereof | INFINITY PHARMACEUTICALS, INC. (US) | 2017-01-17 | — | — | US | disclosed |
| US-9505728-B2 | Triazolone compounds and uses thereof | INCEPTION 2, INC. (US) | 2016-11-29 | — | — | US | disclosed |
| WO-2016160938-A1 | N-(1,3-THIAZOL-2-YL)PYRIMIDINE-5-CARBOXAMIDES AS TRPV3 MODULATORS | ABBVIE INC. (US) | 2016-10-06 | — | — | WO | disclosed |
| US-20120070412-A1 | HCV Inhibitor and Therapeutic Agent Combinations | PTC THERAPEUTICS, INC. (US) | 2012-03-22 | — | — | US | disclosed |
| WO-2012037299-A2 | FATTY ACID SYNTHASE INHIBITORS | GLAXOSMITHKLINE LLC (US) | 2012-03-22 | — | — | WO | disclosed |
| WO-2012037298-A1 | FATTY ACID SYNTHASE INHIBITORS | GLAXOSMITHKLINE LLC (US) | 2012-03-22 | — | — | WO | disclosed |
| WO-2011103546-A1 | TRIAZOLONES AS FATTY ACID SYNTHASE INHIBITORS | GLAXOSMITHKLINE LLC (US) | 2011-08-25 | — | — | WO | disclosed |
| WO-2011056635-A1 | BENZIMIDAZOLES AS FATTY ACID SYNTHASE INHIBITORS | GLAXOSMITHKLINE LLC (US) | 2011-05-12 | — | — | WO | disclosed |
| US-20100137313-A1 | HETEROCYCLIC DERIVATIVES AND METHODS OF USE THEREOF | ASTRAZENECA AB | 2010-06-03 | — | — | US | disclosed |
| US-20100120761-A1 | Bicyclic Heterocyclic Compounds as FGFR Inhibitors | ASTEX THERAPEUTICS LIMITED (GB) | 2010-05-13 | — | — | US | disclosed |
| WO-2009133127-A1 | FUSED BICYCLIC COMPOUNDS AND USE THEREOF AS PI3K INHIBITORS | MERCK SERONO S.A. (CH) | 2009-11-05 | — | — | WO | disclosed |
| WO-2009111547-A1 | 7H-PYRROLO[2,3-H]QUINAZOLINE COMPOUNDS, THEIR USE AS MTOR KINASE AND PI3 KINASE INHIBITORS, AND THEIR SYNTHESIS | WYETH (US) | 2009-09-11 | — | — | WO | disclosed |
| US-20090227575-A1 | 7H-PYRROLO[2,3-H]QUINAZOLINE COMPOUNDS, THEIR USE AS mTOR KINASE AND PI3 KINASE INHIBITORS, AND THEIR SYNTHESIS | WYETH (US) | 2009-09-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100137313-A1 | HETEROCYCLIC DERIVATIVES AND METHODS OF USE THEREOF | SDHA, SDHB, UROD | HTT 3861/4885HPGD 29/4885MEN1 859/4885 |
| US-20120070412-A1 | HCV Inhibitor and Therapeutic Agent Combinations | HAVCR2, SERPINB1, ENPEP | HTT 4273/4885HPGD 1854/4885MEN1 4860/4885 |
| US-20180243298-A1 | TRPV3 MODULATORS | TRPV3, TRPV1, TRPV2 | HTT 3355/4885HPGD 869/4885MEN1 4814/4885 |
| US-20170137407-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | AKT3, PIK3CA, AKT1 | HTT 969/4885HPGD 1385/4885MEN1 806/4885 |
| US-20100120761-A1 | Bicyclic Heterocyclic Compounds as FGFR Inhibitors | FGFR3, FGFR1, FGFR2 | HTT 609/4885HPGD 1246/4885MEN1 2783/4885 |
| US-20090227575-A1 | 7H-PYRROLO[2,3-H]QUINAZOLINE COMPOUNDS, THEIR USE AS mTOR KINASE AND PI3 KINASE INHIBITORS, AND THEIR SYNTHESIS | MTOR, RICTOR, RPS6KA3 | HTT 1050/4885HPGD 2892/4885MEN1 2047/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.